


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

Confirmation No. 9188

FRIDOVICH et al

Atty. Ref.: 1579-580

Serial No. 09/880,125

Group: 1624

Filed: June 14, 2001

Examiner: Habte, K.

For: SUBSTITUTED PORPHYRINS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 31, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each
identified document and a translation or a concise explanation of
each non-English language document (such as a Search Report) is
enclosed herewith.

FRIDOVICH et al
Serial No. 09/880,125
October 31, 2003

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - ☐ a) The required Statement made in item 8 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

FRIDOVICH et al
Serial No. 09/880,125
October 31, 2003

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)



Atty. Docket No.

Serial No.

1579-580

09/880,125

Applicant

FRIDOVICH et al

Filing Date

Group

June 14, 2001

1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,829,984	5/1989	Gordon			
	4,866,054	9/1989	Dori et al			
	5,010,073	4/1991	Kappas et al			
	5,087,438	2/1992	Gordon			
	5,109,016	4/1992	Dixon et al			
	5,192,788	3/1993	Dixon et al			
	5,277,908	1/1994	Beckman et al			
	5,403,834	4/1995	Malfroy-Camine et al			
	5,405,369	4/1995	Selman et al			
	2002/0058643	5/2002	Cherian et al			
	5,563,132	10/1996	Bodaness			
	5,604,199	2/1997	Funanage			
	5,610,293	3/1997	Riley et al			
	5,637,578	6/1997	Riley et al			
	5,874,421	2/1999	Riley et al			
	5,976,498	11/1999	Neumann et al			
	6,013,241	1/2000	Marchal et al			
	6,060,467	5/2000	Buelow et al			
	6,180,620	1/2001	Salvemini			
	6,204,259	3/2001	Riley et al			
	6,214,817	4/2001	Riley et al			
	6,245,758	6/2001	Stern et al			
	6,372,727	4/2002	Crow et al			
	6,395,725	5/2002	Salvemini			
	6,403,788	6/2002	Meunier et al			
	6,417,182	7/2002	Abrams et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 92/08482	5/1992	PCT			
WO 97/06824	2/1997	PCT			
WO 97/06830	2/1997	PCT			
WO 97/06831	2/1997	PCT			
WO 97/33588	9/1997	PCT			
WO 97/33877	9/1997	PCT			
WO 98/58636	12/1998	PCT			
WO 00/04868	2/2000	PCT			
WO 00/72893	12/2000	PCT			

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

Atty. Docket N .

Serial No.

1579-580

09/880,125

Applicant

FRIDOVICH et al

Filing Date

Gr up

June 14, 2001

1624

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Batinic-Haberle et al., "The *Ortho* Effect Makes Manganese(III) *Meso*-Tetrakis-(*N*-Methylpyridinium-2-yl)Porphyrin a Powerful and Potentially Useful Superoxide Dismutase Mimic", The Journal of Biological Chemistry 273(38):24521-24528 (1998)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.